Clinical Trial Search

Primary: Percentage of Participants With Adverse Events (AEs), Including Serious AEs — 100; 100; 28; 48 percentage of participants

Primary: Maximum Observed Concentration (Cmax) of GSK3196165 — 699.92; 1444.88; 3924.10 Nanogram per milliliter (ng/mL)

Primary: Percentage of Participants With HBeAg Seroconversion at Week 48 — 21; 23 Participants

Primary: Number of AEs Per Severity (All Courses) — 40; 27; 8; 15 Number of AEs

Primary: Stage 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)…

Primary: Suck and Swallow Competency in Infants/Children With PWS Who Are in Nutritional Phase 1a — 8; 4; 1; 1 Participants — p=0.930

Primary: Median Time of Overall Survival — 30.7; 28.6 Weeks — p=0.9460

Primary: Number of Participants With Adverse Events (AEs) Related to Cytokine Release Syndrome (CRS) — 5; 9; 8; 7 Participants

Primary: Craving — 6.53; 7.0; 4.74; 4.43 scores on a scale — p=0.05

Primary: Number of Participants With Dose Limiting Toxicity (DLT) With Panitumumab Plus TAS-102 Combination Therapy — 0 Participants

Primary: Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) in Part A of the Study — 3; 3; 3; 3 Participants

Primary: Resectability Rate — 8; 2 Participants

Primary: Primary Site Complete Response Rate — 6; 4 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events, Serious Adverse Events, and Who Withdrew Due to Adverse Events — 33; 3; 8; 1 Participants

Primary: To Determine Platelet Inhibition Before and After Switching for Two Weeks From Clopidogrel to Ticagrelor in Patients With CLI. — 173; 140; 71; 63 P2Y12 reaction units…